References
- Bali V, Ali M, Ali J. (2010). Study of surfactant combinations and development of a novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. Coll Surf B: Biointer 76:410–20
- Chow HHS, Chen Z, Matsuura GT. (1999). Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 88:754–8
- Danielyan L, Schäfer R, Von Ameln-Mayerhofer A, et al. (2009). Intranasal delivery of cells to the brain. Eur J Cell Biol 88:315–24
- Danielyan L, Schäfer R, Von Ameln-Mayerhofer A, et al. (2011). Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 14:3–16
- Hanson LR, Frey II WH. (2007). Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharm 2:81–6
- Hanson LR, Roeytenberg A, Martinez PM, et al. (2009). Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330:679–86
- Illum L. (2004). Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3–17
- Jiang XG, Cui JB, Fang XL, et al. (1995). Toxicity of drugs on nasal mucocilia and the method of its evaluation. Acta Pharmacol Sin 30:848–53
- Kaul M. (2008). HIV’s double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci 13:2484–94
- Kiechel Jean-Rene, Acezat-Mispelter Francoise, Plas Danielle. (1989). United States Patent 4,885,305
- Liang WQ, Fang XL, Gao S, et al. (2003). Biopharmaceutics and pharmacokinetics, 2nd ed. Beijing: People’s Medical Publishing House, 37
- Mahajan HS, Gattani SG. (2010). In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Del 17:19–27
- Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–57
- Mudigonda K, Jukanti R, Apte, SS, et al. (2006). HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice. Biomed Chromatogr 20:1028–32
- Nicolas A, Thierry FV. (2009). The universality of low-energy nano-emulsification. Int J Pharm 377:142–7
- Nottet HS, Persidsky Y, Sasseville VG. (1996). Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 156:1284–95
- Parveen R, Baboota S, Ali J, et al. (2011). Oil based nanocarrier for improved oral delivery of silymarin: in vitro and in vivo studies. Int J Pharm 413:245–53
- Sarker DK. (2005). Engineering of nanoemulsions for drug delivery. Curr Drug Del 2:297–310
- Strazielle N, Ghersi-Egea JF. (2005). Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 15:105–33
- Thorne RG, Frey II WH. (2001). Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinetic 40:907–46
- Yang JP, Liu HJ, Cheng SM, et al. (2009). Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett 449:108–11
- Zhang H, Yao M, Morrison RA, Chong, S. (2003). Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26:768–72
- Zhang Q, Jiang X, Jiang W, et al. (2004). Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 275:85–96